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Abstract
Vascular Ehlers-Danlos syndrome (vEDS) is a rare and severe connective tissue disorder caused by mutations in the collagen type
III alpha I chain (COL3A1) gene. We describe a pathogenetic heterozygous COL3A1 mutation c.3140 G>A, p. Gly1047Asp,
identified using next-generation sequencing, in a 40-year-old Italian female. The genetic test performed on her relatives, which
present different clinical phenotypes, confirmed that they carry the same mutation in heterozygous state. This finding confirms
that mutations causing vEDS have an incomplete penetrance.
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Introduction
Vascular Ehlers-Danlos syndrome (vEDS) is a heritable
connective tissue disorder mainly characterized by severe
arterial and gastrointestinal complications.1 The clinical diag-
nosis of vEDS can be suspected on the basis of criteria estab-
lished in 19972: a characteristic facial aspect (acrogeria); thin
and translucent skin with highly visible subcutaneous blood
vessels; ecchymoses and hematomas; and arterial, digestive,
and obstetrical complications. However, in most individuals,
the diagnosis, in the absence of a family history of the disorder,
is not suspected until arterial aneurysm and/or dissection,
bowel perforation, or organ rupture occur. Therefore, in the
presence of these complications, the genetic analysis of col-
lagen type III alpha I chain (COL3A1) gene is necessary to
confirm the diagnosis.3
COL3A1, encoding type III collagen, is situated on the long
arm of chromosome 2 in position 2q24.3-q31 (Figure 1). Vas-
cular Ehlers-Danlos syndrome is caused by a deficit of type III
collagen, which belongs to the fibrillar collagens. All fibrillar
collagens are homo-/heterotrimers formed by 3 a-chains. Type
III collagen is a homotrimer formed by the binding of 3 a1(III)
chains; the central region of each chain adopts a triple-helix
structure. The amino acid sequence of the triple helix is char-
acterized by repetition of Gly-X-Y sequences, where X and Y
are other amino acids (often proline and hydroxyproline,
respectively), in order to maintain a correct binding of a-mono-
mers (Figure 1). Type III collagen is a fundamental element of
arterial vessels and walls of gastrointestinal tracts. COL3A1’s
product quantitative or qualitative deficit in patients with vEDS
increases the possibility of occurrence of arterial tears or dis-
sections, peculiar tracts of this pathology.
In the present study, we analyzed genotype/phenotype cor-
relation of a COL3A1 mutation c.3140 G>A, p. Gly1047Asp4
identified in an Italian family affected by vEDS. The clinical
and genetic counseling are carried out at the Regional Center of
Ehlers-Danlos Syndrome (Ospedale Maggiore Policlinico,
Milan, Italy) where the proband, a 40-year-old Italian female,
and her relatives have been analyzed (Figure 2). They present
different clinical phenotypes confirming a different penetrance
occurring in different members of the same family.
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A 40-year-old Italian female (III:3, Figure 2) was admitted to
the Regional Center of Ehlers-Danlos Syndrome (Ospedale
Maggiore Policlinico, Milan, Italy) for a hemorrhagic episode
with partial separation of the placenta in the seventh week of
gestation. In 2012, after a second abortion, she underwent 3
surgeries for uterus recanalization. After that, she did not refer
any problems. The clinical history revealed smooth, velvet,
and thin skin, slightly elastic in correspondence of forearms
and extremely translucent with visible veins in correspon-
dence of chest and abdomen, and acrogeria of the hands and
feet (Figure 3). She also referred capillary fragility at the
lower limbs—she underwent sclerotherapy. She had a baby
(IV:1, Figure 2) that was born after 30th week of gestation and
presented lung problems.
At the same time, other members of her family were clini-
cally diagnosed at the Regional Center of Ehlers-Danlos Syn-
drome. Mother’s clinical spectrum (II:2, Figure 2) didn’t reveal
typical vEDS characteristics. In 2012, she had a vascular epi-
sode of aneurysm of hepatic artery that arose the suspect for
vEDS. Brother’s clinical spectrum (III:1, Figure 2) shows
slightly elastic skin in correspondence of knees, elbows, and
hands; visible veins on chest and abdomen; and atrophic scars.
Whereas the sister (III:2, Figure 2) died when she was a
7-month-old baby. Proband’s daughter (IV:1, Figure 2) had
lung problems, but other clinical examinations will be
Figure 1. COL3A1 Gene. A, Yellow arrow indicates the location of COL3A1 gene. B, Schematic representation of collagen fiber; the COL3A1











Figure 2. Pedigree. In black member of the family heterozygous of the
c.3140G>A (p.Gly1047Asp) mutation in exon 44 of COL3A1 gene. I:1
and I:2 were died at 70 and 80 years for lung tumor and ictus,
respectively.
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necessary to fully understand her phenotype. The remaining
members of the family (II:3, II.4, III:4; Figure 2) were clini-
cally evaluated but they did not show relevant clinical issues.
We didn’t perform genetic test on I:1 and I:2 (Figure 2) because
they died for lung tumor and ictus at 70 and 80 years, respec-
tively, before this clinical investigation.
Haloplex Target Enrichment
We adopted next-generation sequencing (NGS) for investi-
gating genomic regions of interest through target enrich-
ment. It was performed by means of Haloplex Target
Enrichment kit (Agilent Technologies, CA, USA). Probes
for all coding exons, including intron–exon boundaries,
were designed by the Haloplex SureDesign website
(www.genomics.agilent.com). The 9 genes included in the
design were selected on the basis of their clinical character-
istics (www.le.ac.uk/ge/collagen; Table 1). The total region
size was 100.336 kilo base pair (kbp) for an actual analyzed
target of 99.718 kbp bases. Enrichment was performed
according to supplier’s protocol (version D.6, August
2014). A total of 225 ng DNA was digested in 8 different
restriction reactions during 30 minutes at 37C. The 8 reac-
tion digestions were combined into a single hybridization
mix containing target-specific probes. Hybridization reac-
tion was performed in 3-hour reaction at 54C. Probes were
labeled with biotin and designed to hybridize to both ends
of the digested fragments, therefore generating circular
fragments containing 1 nick. Then, the DNA probe hybrids
were captured with streptavidin beads to eliminate linear,
nontarget DNA fragments. In a second ligation reaction, the
remaining nick was closed to complete circularization. DNA
captured was eluted from the beads and amplified by poly-
merase chain reaction, followed by a final purification reac-
tion with AMPure XP beads (Beckman Coulter, Fullerton,
California).
Finally, the concentration of each library was measured
using Tape Station software A.02.01 (SR1), KGGSeq software
3.0 and after different elution with Tris Edta (TE) arrived at
4 nmol. Then the final pool was obtained by mixing different
genomic libraries, and the ideal final concentration is 8 pmol
(ideal concentration for cluster density about 900/1000
K/mm2). Captured genomic libraries were sequenced to gen-
erate 2  150 bp paired end reads using the Illumina MiSeq,
CA, USA.
Next-Generation Sequencing Data Analysis
To analyze the generated FastQ files (file format used to store
biological sequence and its quality score), a workflow was set
up using Galaxy software (https://orione.crs4.it/).5 FastQ files
were evaluated by quality and trimming, aligned, and mapped
to the human reference genome (GRCh37/hg19) using
Burrows-Wheeler Aligner.6,7 Alignments including sorting,
merging, indexing, and generating alignments in a per-
position format were manipulated by SAM tools8,9 to generate
BAM (binary format for storing sequence) file. Local realign-
ment, base quality recalibration, and variant calling were per-
formed using Genome Analysis Toolkit version 2.0 (Broad
Institute, Cambridge, Massachusetts),10 applying this quality
parameters—coverage >20, base quality score >30, and
Figure 3. Acrogeria. A, Particular of hand. B, Particular of foot of a proband.
Table 1. NGS Panel: The Genes Included in the NGS Panel Are
Clinically Implicated in EDS.
Gene Phenotype Chromosome
ADAMTS2 EDS type VIIC chr5q.35.3
B4GALT7 EDS progeroid type 1 chr5q35.3
CHST14 EDS musculocontractural type 1 chr15q15.1
COL3A1 EDS type IV chr2q32.2
COL5A1 EDS classic type chr9q34.3
COL5A2 EDS classic type chr2q32.2
PLOD1 EDS type VI chr1p36.22
PLOD3 Lysyl hydroxylase 3 deficiency chr7q22.1
TNXB EDS due to tenascin X deficiency chr6p21.33
Abbreviations: ADAMTS2, ADAM Metallopeptidase With Thrombospondin
Type 1 Motif 2; B4GALT7, Beta-1, 4-Galactosyltransferase 7; CHST14, Carbo-
hydrate Sulfotransferase 14; COL3A1, collagen type III alpha I chain; COL5A1,
collagen type V alpha I chain; COL5A2, collagen type V alpha II chain; EDS,
Ehlers-Danlos syndrome; PLOD1, Procollagen-Lysine,2-Oxoglutarate 5-Diox-
ygenase 1; PLOD3, Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 3;
TNXB, Tenascin XB.
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mapping quality >20. Variants that did not pass these quality
values were removed.
Finally, the variant calling files were filtered through differ-
ent parameters as genotype quality filters, gene feature filters
(missense, splicing, frameshift), and functional impact filters
using KGGSeq software.11
Sanger Sequencing
The variants found with NGS target enrichment method were
confirmed by Sanger method using Big Dye Terminator Cycle
Sequencing kit (Applied Biosystems, Life Technologies, CA,
USA), followed by capillary electrophoresis on an ABI3130xl
(Applied Biosystems). The electropherograms were analyzed
by Sequencer software v5.1.
Data Analysis of Missense Variants
To investigate the pathogenetic properties of missense variants,
different software were used—SIFT/PROVEAN, Polyphen-2,
Mutation Taster, Grantham Distance, and Align GVGD, which
were based on sequence homology, the physiochemical similar-
ity between the alternate amino acids, effect on an amino acid
substitution on the structure, and function of a protein and con-
servation level of the amino acid residue among species,
respectively.12,13
Results
Genetic analysis done on the proband (III:3; Figure 2) by NGS
target enrichment approach identified a mutation in exon 44 of
COL3A1 gene: c.3140G>A, p. Gly1047Asp in heterozygous
state (Figure 4)4 (www.le.ac.uk/ge/collagen/), confirmed by
Sanger method on a new DNA extraction. The clinical counsel-
ing on mother, brother, and daughter (II:2, III:1, IV:1; Figure 2)
and genetic analysis, by Sanger method, revealed that they
were carrier of the same mutation in heterozygous state,
whereas the remaining members of the family were found neg-
ative (II:3, II:4, III:4; Figure 2).
The c.3140G>A, p.Gly1047Asp mutation is a missense var-
iant that leads to the substitution of a neutral amino acid, the
glycine, with a polar one, the aspartic acid. It is located in the
triple-helix region of the protein. As previously described, type
III collagen consists of repetition of Gly-X-Y, the peculiar
feature of the 3 a-chains that forms collagen type III. The
substitution of the first glycine, a neutral amino acid, with a
polar amino acid modifies the characteristic a-helix structure,
and this causes qualitative and quantitative defects of mature
type III collagen.14 The pathogenicity features of this substitu-
tion has been confirmed by bioinformatic analyses. In particu-
lar, SIFT, PROVEAN, Polyphen-2, Mutation Taster, Grantham
Distance, and Align GVGD12,13 indicate that p.Gly1047Asp
substitution is damaging and alters the structure of the protein.
Moreover, the missense variant didn’t explain the different
phenotypes of other family members (Figure 2).15 The proband
(III:3, Figure 2) shows the main characteristics of vEDS,
whereas mother and brother showed isolate vascular episodes;
up to date the daughter is under analysis. The phenotypical
variability of affected members within the same family con-
firmed that genetic testing is essential to confirm the diagnosis
of vEDS.
Discussion
In this study, we described a COL3A1 missense mutation
c.3140G>A, p.Gly1047Asp identified in an Italian family (Fig-
ure 4). It is a substitution of a glycine, neutral amino acid, with
an aspartic acid, polar amino acid, located in triple-helix region
of the protein structure. Bioinformatic analysis12,13,16,17 con-
firmed its pathogenic properties. The clinical counseling
revealed a different penetrance occurring in the same family.15
In fact, the proband (III:3, Figure 2) had the main charac-
teristics of vEDS—smooth, velvet, and thin skin with visible
veins in correspondence of abdomen and chest and acrogeria at
the feet and hands. She shows fragility of veins, capillaries, and
Figure 4. Electropherogram. Missense mutation c.3140G>A, p.Gly1047Asp identified in exon 44 of COL3A1 gene.
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tissues; in fact, she needed to undergo 3 surgeries to achieve
uterus recanalization after the second abortion. Her mother
(II:2) and her brother (III:1) had isolated vascular episode; the
clinical and genetic diagnoses of the proband suggest the pos-
sibility of familiar vEDS that was confirmed by genetic testing
of COL3A1 performed on the other members of the family by
Sanger sequencing.
At the time of the first counseling, the proband was pregnant
and she had the baby at the 30th week of gestation. She was
convinced by her clinical and genetic data to try genetic test on
her baby. The daughter resulted to be carrier of the same muta-
tion in heterozygous state, but the clinical phenotype is incom-
plete for the early age of the baby. The other members of the
family were found negative (Figure 2).
The affected members of family follow a treatment with
celiprorol, a cardioselective b-blocker with b2 antagonist vaso-
dilatatory properties. Celiprorol was reported to reduce heart
rate and pulsatile pressures in essential hypertension15 and
could decrease the continuous and pulsatile mechanical stress
on collagen fibers within the arterial wall.
In conclusion, c.3140G>A, p. Gly1047Asp4 is a pathoge-
netic mutation. Our analysis shows that this mutation influ-
ences the phenotype with different penetrance, as
demonstrated by different disease manifestations in different
members of the same family.18
We hypothesize that the heterozygous state of the mutation
is the possible determinant of different phenotypes observed. In
any case, we cannot exclude other genetic factors influencing
the expression of this mutation in this family. Ultimately, this
study confirmed that the genetic test is essential to evaluate the
nature and the risks of the complications in patients with vEDS.
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